Biogen Inc. (ETR:IDP)
149.15
+1.00 (0.67%)
Dec 22, 2025, 5:35 PM CET
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
€1,128,096
Profits / Employee
€180,266
Market Cap
21.80B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Bayer Aktiengesellschaft | 91,864 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 59,020 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,784 |
Biogen News
- 4 days ago - Biogen (BIIB) Set to Advance New Drug BIIB145 from Collaboration - GuruFocus
- 6 days ago - Eisai: "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List - Finanz Nachrichten
- 6 days ago - Nasdaq 100 Movers: BIIB, MSTR - Nasdaq
- 7 days ago - Nasdaq-100 Shake-Up: These 6 Stocks Are In, 6 Are Out — And It Could Trigger Big Moves - Benzinga
- 8 days ago - Biogen: Alzheimer's Disease Treatment Needs More Real-World Data - Seeking Alpha
- 9 days ago - Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - Seeking Alpha
- 10 days ago - Biogen (BIIB) Sees Target Price Increase by Morgan Stanley | BIIB Stock News - GuruFocus
- 12 days ago - BIIB: Analyst Raises Price Target, Maintains Equal-Weight Rating | BIIB Stock News - GuruFocus